Amylyx Pharmaceuticals, Inc（AMLX）美股招股说明书 S-1 （2022-01-03修订版）（英文版）（301页）.pdf

1、S-1/A 1 d155225ds1a.htm S-1/ATable of ContentsAs filed with the Securities and Exchange Commission on January 3,2022.Registration No.333-261703UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Amendment No.1toFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933Amylyx Pharma

2、ceuticals,Inc.(Exact name of registrant as specified in its charter)Delaware 2834 46-4600503(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification No.)43 Thorndike St.Cambridge,Massachusetts 02141(617)682-0917

3、(Address,including zip code,and telephone number,including area code,of registrants principal executive offices)Joshua B.Cohen,Co-Chief Executive OfficerJustin B.Klee,Co-Chief Executive OfficerAmylyx Pharmaceuticals,Inc.43 Thorndike St.Cambridge,Massachusetts 02141(617)682-0917(Name,address,includin

4、g zip code,and telephone number,including area code,of agent for service)Copies to:Mitchell S.Bloom,Esq.Benjamin K.Marsh,Esq.Goodwin Procter LLP100 Northern AvenueBoston,Massachusetts 02210(617)570-1000 Lisa Firenze,Esq.Stuart M.Falber,Esq.Jeffries Oliver-Li,Esq.Wilmer Cutler Pickering Hale and Dorr

5、 LLP7 World Trade Center250 Greenwich StreetNew York,New York 10007(212)230-8800Approximate date of commencement of proposed sale to the public:As soon as practicable after this Registration Statement is declared effective.If any of the securities being registered on this form are to be offered on a

6、 delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 checkthe following box.If this form is filed to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,check the following box and list the Securities Actregistration statement